With a median follow-up of 10 years after coronary artery bypass grafting (CABG), patients who received a radial artery graft rather than a saphenous vein graft as a second conduit were less likely to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Radial artery graft conferred lower 15-year all-cause ...

New long-term data from the CSP 474 trial offers a challenge to some of the conventional wisdom around graft choice in CABG surgery and may further the debate over recent guideline recommendations.

Supporting saphenous vein grafts used in CABG with a novel external stent-like device did not decrease the degree of intimal hyperplasia seen at 1 year compared with unsupported grafts, but ...

Please provide your email address to receive an email when new articles are posted on . Use of an external saphenous vein graft support device did not improve intimal hyperplasia area in patients ...

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line ...

ANAHEIM, CA — A new trial shows the combination of aspirin plus ticagrelor (Brilinta, AstraZeneca) resulted in significant improvement in saphenous vein graft (SVG) patency at 12 months compared with ...